Filing Flows › Cardiff Oncology (CRDF) › Q1 2025
Cardiff Oncology (CRDF) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Cardiff Oncology (CRDF) reported revenue of $109K for the first quarter 2025 (Q1 2025), -47% from a year earlier and -28% from the quarter before.
Cardiff Oncology, Q1 2025: revenue $109K (-47% year over year), net loss $13.4M, operating cash flow −$12.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $109K | -28% | -47% |
| Operating profit | −$14.4M | — | — |
| Net earnings | −$13.4M | — | — |
| Operating cash flow | −$12.8M | — | — |
What changed
Revenue was $109K in Q1 2025, down 47% year over year and down 28% from the previous quarter.
Operating costs exceeded revenue by $14.4M, an operating margin of -13194.5%. Total costs grew 30% against a revenue fall of 47%. The fastest-growing cost line was Research & development (+31%). The quarter ended with a net loss of $13.4M, wider than the previous quarter's $11.8M loss.
Operating cash flow was −$12.8M. Non-cash charges added back $93K of depreciation and $1.4M of share-based compensation. Working capital and other items used $818K.
Questions
What was Cardiff Oncology's revenue in the first quarter 2025?
Cardiff Oncology (CRDF) reported revenue of $109K for the first quarter 2025 (Q1 2025), -47% from a year earlier and -28% from the quarter before.
Source: Cardiff Oncology 10-Q on SEC EDGAR.